Search

everythinglearnresearchcommunity

for

Search:↓

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Increased hair shedding after starting Dutasteride is normal and indicates treatment efficacy, as it triggers a synchronized shedding phase to make way for stronger hair growth. It is advised to continue with the current treatment plan and assess results in 9 to 12 months.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

A user shared their experience with hair recovery after a second shedding phase while using Finasteride. They advise staying consistent with treatment, as it can take 1-2 years or more to see results, and also mention using Ketoconazole but are unsure of its effectiveness.

The user has been using finasteride for five years and minoxidil foam for 1.5 years to combat hair loss, experiencing significant regrowth after an initial shedding phase with minoxidil. They shared progress pictures and discussed treatment experiences, including the addition of minoxidil to their regimen after noticing reduced efficacy with finasteride alone.

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.

The user experienced significant hair regrowth using topical finasteride and minoxidil but faced a prolonged shedding phase, leading them to increase the finasteride dose and add oral dutasteride. Despite concerns about shedding, they remain hopeful for regrowth and are supplementing with Vitamin D.

The user experienced hair regrowth using finasteride every other day and topical minoxidil but is currently going through a shedding phase. Despite the shedding, progress is evident, and users suggest patience and possibly adding microneedling to improve results.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Topical melatonin may have positive effects on hair loss by keeping hair in the growing phase. Users are discussing product recommendations and DIY methods for incorporating melatonin into their hair care routine.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.

Hair loss treatments mentioned: finasteride, dutasteride, and hair transplant. Misunderstandings in conversation involve wordplay on "bill," "check," and "to pay" sounding like names and phrases.

Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hair follicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

People discussing their experiences with hair loss treatments found that switching from finasteride (Fin) to dutasteride (Dut) often resulted in improved hair thickness and health, despite some experiencing side effects or shedding phases. Some users switched due to diminishing results with Fin, while others were curious about the potential for better outcomes with Dut.

The user experienced significant hair improvement using finasteride, minoxidil, ketoconazole shampoo, and microneedling over a year, with no side effects. They used topical minoxidil and reported shedding phases, but no current shedding as of March 2026.

The user shared their hair loss treatment progress using Finasteride, Dutasteride, and Minoxidil, noting initial irritation with topical Minoxidil and experiencing shedding phases. They reported no side effects and encouraged others to try this regimen for alopecia.

The conversation discusses hair shedding experienced by users on minoxidil and finasteride treatments, with some considering additional options like spironolactone and dutasteride. Many users report experiencing a second shedding phase but are advised to continue treatment as it may lead to thicker hair regrowth.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation discusses hair loss treatments, specifically the transition from topical to oral minoxidil and finasteride, and the associated shedding phase. Users advise patience and consistency, noting that shedding is common and improvement may take several months.